Compare VIDA & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIDA | IMA |
|---|---|---|
| Founded | 2022 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 66.3M |
| IPO Year | 2026 | 2021 |
| Metric | VIDA | IMA |
|---|---|---|
| Price | $1.60 | $4.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 110.6K | 12.3K |
| Earning Date | 11-19-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $3.94 |
| 52 Week High | $4.25 | $9.10 |
| Indicator | VIDA | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 30.75 |
| Support Level | N/A | $3.94 |
| Resistance Level | $2.79 | $6.13 |
| Average True Range (ATR) | 0.15 | 0.25 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 10.00 | 1.22 |
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.